Related Experiment Video
Updated: Jul 6, 2026
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53: a guide to apoptosis
Erik Meulmeester1, Aart G Jochemsen
1Department of Biochemistry I, University of Goettingen, Humboldtallee 23, D-37073, Germany. emeulme@gwdg.de
Abstract:
Approximately 50% of sporadic human tumors harbor somatic mutations in the p53 gene locus, while germ line mutations confer a high familial risk and are associated with Li-Fraumeni Syndrome patients. The p53 tumor suppressor protein is often referred to as the "guardian of the genome" since its response to DNA-damage or checkpoint failure gives rise to a series of anti-proliferative responses. One of the most important functions of p53 is its ability to induce apoptosis, while disruption of this route can promote tumor progression and chemo resistance. Besides its ability to promote apoptosis through transcription dependent mechanisms, p53 may also be able to activate apoptosis independent of transcriptional regulation. Therefore, to ensure normal cell growth, p53 levels and activity are tightly regulated. Upon diverse forms of cellular stress the steady state levels and transcriptional activity of p53 are considerably increased. The stabilization and activation of p53 are a result of hindered inhibition by its negative regulators, e.g. Mdmx (also known as Mdm4) and Mdm2, while on the other hand activators such as HIPK2 and DYRK2 enhance the p53 response. The continually increasing understanding of the mechanisms of regulation of p53 may provide the basis for new drug designs that could eventually lead to therapeutics to reactivate p53 in cancers.
Insights
The p53 protein, or "guardian of the genome," is crucial for preventing cancer by inducing apoptosis. Understanding its regulation by inhibitors like Mdm2 and activators like HIPK2 offers new therapeutic targets for reactivating p53 in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Somatic mutations in the p53 gene occur in ~50% of human tumors.
- Germline mutations in p53 are linked to Li-Fraumeni Syndrome, a high familial cancer risk.
- p53, the "guardian of the genome," is vital for anti-proliferative responses to DNA damage and checkpoint failure.
Purpose of the Study:
- To explore the regulatory mechanisms governing p53 protein levels and activity.
- To investigate the role of p53 in apoptosis, both transcription-dependent and independent.
- To identify potential therapeutic strategies targeting p53 regulation for cancer treatment.
Main Methods:
- Review of existing literature on p53 regulation and function.
- Analysis of the roles of p53 negative regulators (Mdmx, Mdm2) and activators (HIPK2, DYRK2).
- Examination of p53's involvement in apoptotic pathways.
Main Results:
- p53 activity is tightly regulated to ensure normal cell growth.
- Cellular stress significantly increases p53 levels and transcriptional activity.
- p53 stabilization and activation result from reduced inhibition by Mdmx/Mdm2 and enhanced activation by HIPK2/DYRK2.
Conclusions:
- Understanding p53 regulatory mechanisms is key to developing novel cancer therapeutics.
- Targeting p53 regulators could lead to strategies for reactivating p53 in various cancers.
- p53's dual role in transcription-dependent and independent apoptosis highlights its complex tumor suppressive functions.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:23Abnormal Proliferation
02:36DNA Damage Can Stall the Cell Cycle
02:36DNA Damage can Stall the Cell Cycle
01:23Negative Regulator Molecules
01:22Cellular Injury V: Apoptosis and Autophagy